Horizon Discovery Group plc and Redx Pharma plc sign cancer research collaboration

4 September 2015

Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, and Redx Pharma plc, today announce a research collaboration to progress Redx’s novel pan-RAF inhibitor program, for out-licensing in oncology indications including colorectal cancer, the fourth most common cancer and the second most common cause of cancer death in the UK.

 
  • Collaboration to progress  Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing
  • Horizon leveraging its proprietary gene editing, cell line and drug discovery technology platforms and know how
  • Future pharmaceutical partnering deal expected to deliver a material return to Horizon on its investment from any upfront payment, a share of future milestones and a share of future product royalties
Redx’s pan-RAF inhibitor program has identified next generation novel small molecule inhibitors of RAF kinases as potential treatments for colorectal and other potential cancers. These next generation pan-RAF inhibitors have been designed to overcome resistance mechanisms seen with first generation RAF inhibitors in colorectal cancer. As part of the collaboration, Horizon will deploy its proprietary gene editing, cell line and drug discovery technology platforms and know how to help explore the mode of action of Redx’s pan-RAF inhibitors and support Redx as it seeks to rapidly move this rare class of compounds towards partnering.

Under the terms of the agreement, Horizon and Redx will bear costs proportionate to respective research activities.  The successful partnering of a program asset with a pharmaceutical company is expected to deliver a material return on Horizon’s investment from any upfront payment, a share of future milestones and a share of future product royalties.

 Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery Group, commented:

 “Horizon’s expertise throughout the drug discovery and development continuum, from genomic sequence to patient treatment, enables pharmaceutical and biotech companies to address the challenges and hurdles that could prevent them from realising the potential of their promising drug candidates. This partnership demonstrates how Horizon is able to strike innovative deals in which it deploys its proprietary technology platforms, know-how and internal resources to leverage significant upside potential for its shareholders.

“We are delighted to be able to support Redx as it moves towards securing partnerships for these novel assets and look forward to similar collaborations with other innovative drug development companies.”   Neil Murray, Chief Executive of Redx Pharma plc, commented:

“Our pan-RAF inhibitor program is dealing with novel biology and is at a very interesting point.  Our partnership with Horizon will enable us to detail at molecular level the effects of our pan-RAF inhibitors and help to progress this very promising program as we seek to secure a license partner for this asset.”

 For further information from Horizon Discovery Group plc, please contact:

 Horizon Discovery Group plc

 Dr. Darrin Disley CEO / Richard Vellacott CFO

 Tel: +44 (0) 1223 655580

  Zyme Communications (Trade and Regional Media)

 Katie Odgaard

 Tel: +44 (0)7787 502 947

 Email: katie.odgaard@zymecommunications.com

  Consilium Strategic Communications (Financial Media and Investor Relations)

 Amber Fennell / Jessica Hodgson / Matthew Neal / Laura Thornton

 Tel: +44 (0) 20 3709 5701

 Email: horizon@consilium-comms.com

 

 Panmure Gordon & Co. (NOMAD)

 Corporate Finance: Freddy Crossley / Fabien Holler / Duncan Monteith

 Broking: Tom Salvesen

 Tel: +44 20 7886 2500

 

About Redx Pharma plc

 www.redxpharm.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary (patent-protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 



Looking for something specific?